Sponsored by Abbott Products Operations AG, Switzerland and co-organised by Health Outcomes Strategies GmbH
Despite the promise of generics (Gx) in lowering costs there are concerns around outcomes and total healthcare costs which are currently not addressed in generics policies. This workshop will examine the concerns with generics policies and the need for more rational off-patent policies in order to strengthen healthcare systems and widen the discussion beyond the current paradigm of from lowest-price-priority to value-based priority (cost per health outcome).
The speakers will build on an overview of healthcare policies regulating on-patent and off-patent pharmaceuticals in relation to healthcare efficiency and the underlying definitions before presenting evidence around the impact of such policies on health outcomes, access to drugs and economic parameters as well as considering funding scenarios.
Alternative models for value based decision making and core drivers of value will be discussed and elaborated with the audience by using a structured group discussion approach.
Presentations & discussion
N Maniadakis, Professor, National School of Public Health, Greece
Z Kalo, Professor, Eötvös Loránd University (ELTE), Hungary
J Shen, Abbott Products Operations AG, Switzerland
H Chung, Head of Health Policy Research, Swiss Re Services ltd., UK
D Brixner, Professor, Pharmacotherapy Outcomes Research, University of Utah, USA
AP Holtorf, Health Outcomes Strategies GmbH, Switzerland